Dexcom Inc (Dexcom) designs, develops, and commercializes continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and healthcare providers in the hospital for the treatment of diabetes. Its major products include Dexcom G6 CGM system, Dexcom G7 system, Dexcom Share, and Dexcom Clarity diabetes management software. Dexcom’s G6 is a real-time, CGM device indicated for the management of diabetes in persons aged two years and older. Dexcom G6 system eliminates fingersticks for calibration and diabetes treatment decisions.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

DexCom's research and development (R&D) initiatives primarily focus on engineering and research expenses related to sensing technology, clinical trials, regulatory fees, quality assurance programs, employee compensation, and business process outsourcing. The company maintains an active research program that oversees clinical efforts and supports investigator-initiated studies, industry-sponsored studies utilizing Dexcom CGM Systems, as well as studies conducted by nonprofits or research consortia. The R&D unit of DexCom in San Diego, California, is responsible for managing the company's research and development activities, including engineering, research, clinical trials, and regulatory compliance. In FY2025, the company spent US$599.1 million on R&D activities, which as a percentage of revenue stood at 12.8% and grew 8.5% YoY.